BioMarin Pharmaceutical BMRN · NASDAQ
$58.51 +1.77% (+$1.02)
Summary
48 / 100 · Bulios Score
What speaks for it
- Earnings per share grew by 34% a year over the last 3 years.
- Out of every 100 USD of revenue, 22 USD is left as free cash.
- Analysts expect revenue to grow by 22% this fiscal year.
What to watch
- Repaying its net debt would take 8.6 years of operating profit.
- The share price is above the Bulios Fair Price.
- Out of every 100 USD of revenue, only 2.1 USD is left as net profit.
- It earns only 1.2 USD a year on every 100 USD of invested capital.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 152.5 USD for 1 USD of yearly profit. Over the last five years it was 78.1 USD on average.
Valuation in detailIs it growing?
Yes, fastRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 12% a year over 5 years. Over the last 3 years it grew by 15% a year. For the next fiscal year analysts expect revenue to grow by 22%. Earnings per share grew by 34% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 24 USD
- Research and development 29 USD
- Sales and administration 39 USD
- Taxes and other 5.9 USD
- Net profit 2.1 USD
Net profit, industry median (Biotechnology) -7.1 USD
Out of every 100 USD of revenue, 2.1 USD is left as net profit.
Profitability in detailIs it financially healthy?
MostlyRepaying all its debt would take 5.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 29
- Hold 12
- Sell 0
Today's price within the analysts' price targets
The average target of $90.88 is 55% above today's price. 71% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 98%
- Royalty And Other 1.7%
By region
- UNITED STATES 49%
- Europe 28%
- Rest Of World 12%
- Latin America 11%
Product brings in 98% of revenue.
Segments in detail